Real-World Analysis of the Efficacy of Bimatoprost Sustained-Release Glaucoma Implant Where American Indians Comprise the Largest Minority Population

References

• Tham YC, Li X, Wong TY., et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121(11):2081–2090. doi:10.1016/j.ophtha.2014.05.013
   PubMed Web of Science ®Google Scholar
• Allison K, Patel D, Alabi O. Epidemiology of glaucoma: the past, present, and predictions for the future. Cureus. 2020;12(11):e11686. doi:10.7759/cureus.11686
   PubMed Web of Science ®Google Scholar
• Garway-Heath DF, Crabb DP, Bunce C, et al. Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. Lancet. 2015;385(9975):1295–1304. doi:10.1016/S0140-6736(14)62111-5
   PubMed Web of Science ®Google Scholar
• Boland MV, Ervin A-M, Friedman DS, et al. Comparative effectiveness of treatments for open-angle glaucoma: a systematic review for the u.s. Preventive services task force. Ann Intern Med. 2013;158(4):271–279. doi:10.7326/0003-4819-158-4-201302190-00008
   PubMed Web of Science ®Google Scholar
• Kass MA. The ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120(6):701–713. doi:10.1001/archopht.120.6.701
   PubMed Web of Science ®Google Scholar
• Group CN. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol. 1998;126(4):487–497. doi:10.1016/S0002-9394(98)00223-2
   PubMed Web of Science ®Google Scholar
• Heijl A. Reduction of intraocular pressure and glaucoma progression: results from the early manifest glaucoma trial. Arch Ophthalmol. 2002;120(10):1268–1279. doi:10.1001/archopht.120.10.1268
   PubMed Web of Science ®Google Scholar
• Gedde SJ, Vinod K, Wright MM, et al. Primary open-angle glaucoma preferred practice pattern®. Ophthalmology. 2021;128(1):1.
   Web of Science ®Google Scholar
• Fechtner RD, Godfrey DG, Budenz D, et al. Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications. Cornea. 2010;29(6):618–621. doi:10.1097/ICO.0b013e3181c325b2
   PubMed Web of Science ®Google Scholar
• Patterson E. Open-angle glaucoma 365.10. In: Roy and Fraunfelder’s Current Ocular Therapy. Elsevier; 2008:504–508.
   Google Scholar
• Schwartz GF, Quigley HA. Adherence and persistence with glaucoma therapy. Surv Ophthalmol. 2008;53(6):S57–S68. doi:10.1016/j.survophthal.2008.08.002
   PubMed Web of Science ®Google Scholar
• Nordstrom BL, Friedman DS, Mozaffari E, et al. Persistence and adherence with topical glaucoma therapy. Am J Ophthalmol. 2005;140(4):598.e1–598.e11. doi:10.1016/j.ajo.2005.04.051
   PubMed Web of Science ®Google Scholar
• Olthoff C, Schouten J, Vandeborne B, et al. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review. Ophthalmology. 2005;112(6):953–961.e7. doi:10.1016/j.ophtha.2004.12.035
   PubMed Web of Science ®Google Scholar
• Medeiros FA, Walters TR, Kolko M, et al. Phase 3, randomized, 20-month study of bimatoprost implant in open-angle glaucoma and ocular hypertension (ARTEMIS 1). Ophthalmology. 2020;127(12):1627–1641. doi:10.1016/j.ophtha.2020.06.018
   PubMed Web of Science ®Google Scholar
• Bacharach J, Tatham A, Ferguson G, et al. Phase 3, randomized, 20-month study of the efficacy and safety of bimatoprost implant in patients with open-angle glaucoma and ocular hypertension (ARTEMIS 2). Drugs. 2021;81(17):2017–2033. doi:10.1007/s40265-021-01624-9
   PubMed Web of Science ®Google Scholar
• Varma R. Prevalence and risk indicators of visual impairment and blindness in Latinos: the Los Angeles Latino Eye Study. Ophthalmology. 2004;111(6):1132–1140. doi:10.1016/j.ophtha.2004.02.002
   PubMed Web of Science ®Google Scholar
• Sommer A. Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans. The Baltimore eye survey. Arch Ophthalmol. 1991;109(8):1090–1095. doi:10.1001/archopht.1991.01080080050026
   PubMed Web of Science ®Google Scholar
• Tielsch JM. Racial variations in the prevalence of primary open-angle glaucoma: the Baltimore eye survey. JAMA. 1991;266(3):369–374. doi:10.1001/jama.1991.03470030069026
   PubMed Web of Science ®Google Scholar
• Kapetanakis VV, Chan MPY, Foster PJ, et al. Global variations and time trends in the prevalence of primary open angle glaucoma (POAG): a systematic review and meta-analysis. Br J Ophthalmol. 2016;100(1):86–93. doi:10.1136/bjophthalmol-2015-307223
   PubMed Web of Science ®Google Scholar
• Girkin CA. African Descent and Glaucoma Evaluation Study (ADAGES): II. Ancestry differences in optic disc, retinal nerve fiber layer, and macular structure in healthy subjects. Arch Ophthalmol. 2010;128(5):541–550. doi:10.1001/archophthalmol.2010.49
   PubMedGoogle Scholar
• Flanagin A, Frey T, Christiansen SL. Updated guidance on the reporting of race and ethnicity in medical and science journals. JAMA. 2021;326(7):621–627. doi:10.1001/jama.2021.13304
   PubMed Web of Science ®Google Scholar
• Mansberger SL, Romero FC, Smith NH, et al. Causes of visual impairment and common eye problems in northwest American Indians and Alaska natives. Am J Public Health. 2005;95(5):881–886. doi:10.2105/AJPH.2004.054221
   PubMed Web of Science ®Google Scholar
• Woodward MA, Hughes K, Ballouz D, et al. Assessing eye health and eye care needs among north American native individuals. JAMA Ophthalmol. 2022;140(2):134–142. doi:10.1001/jamaophthalmol.2021.5507
   PubMed Web of Science ®Google Scholar
• Xu W, Zhou P, Kansara ND, Frankfort BJ, Blieden LS, Chang PT. Intraocular pressure and eyedrop usage reduction with intracameral bimatoprost implant. J Ocul Pharmacol Ther. 2023;39(6):398–403. doi:10.1089/jop.2023.0013
   PubMed Web of Science ®Google Scholar
• Stamer WD, Perkumas KM, Kang MH, Dibas M, Robinson MR, Rhee DJ. Proposed mechanism of long-term intraocular pressure lowering with the bimatoprost implant. Invest Opthalmol Vis Sci. 2023;64(3):15. doi:10.1167/iovs.64.3.15
   PubMed Web of Science ®Google Scholar
• Weinreb RN, Bacharach J, Brubaker JW, et al. Bimatoprost implant biodegradation in the phase 3, randomized, 20-month ARTEMIS studies. J Ocul Pharmacol Ther. 2023;39(1):55–62. doi:10.1089/jop.2022.0137
   PubMed Web of Science ®Google Scholar
• Sleath B, Blalock S, Covert D, et al. The relationship between glaucoma medication adherence, eye drop technique, and visual field defect severity. Ophthalmology. 2011;118(12):2398–2402. doi:10.1016/j.ophtha.2011.05.013
   PubMed Web of Science ®Google Scholar
• Newman-Casey PA, Niziol LM, Gillespie BW, et al. The association between medication adherence and visual field progression in the collaborative initial glaucoma treatment study. Ophthalmology. 2020;127(4):477–483. doi:10.1016/j.ophtha.2019.10.022
   PubMed Web of Science ®Google Scholar